2020 Annual Meeting Program
Schedule (subject to change)
NOTE: all times are Eastern Daylight Time

F R I D A Y , J U L Y  2 4

6:00-6:05 PM  
**Introduction**
Timothy Murray, MD, MBA and Philip Ferrone, MD

6:05-6:20 PM  
**Retinal Cell Therapies Symposium**
Moderators: Steven Becker, PhD; Russell Van Gelder, MD, PhD

New Imaging Modalities for Monitoring Retinal Disease, Steven Becker, PhD

Barriers Facing Cell Replacement Therapies, Russell Van Gelder, MD, PhD

6:20-6:40 PM  
**Technology Symposium: Updates in Artificial Intelligence (AI), Augmented Reality and Robotics**
Moderator: Linda Lam, MD, MBA

Multicenter, Head-to-Head, Real-World Validation Study of Artificial Intelligence Diabetic Retinopathy Screening Systems (AIDRSS), Aaron Lee, MD, MSCI

Augmented Reality Device Oculenz- Role in Improving Functional Vision in Patients With Age-Related Macular Degeneration, Linda Lam, MD, MBA

Translational Applications of Deep Learning in Retinopathy of Prematurity, J. Peter Campbell, MD, MPH

Time Independence, Optimized Surgical Steps - the Promise of Robotics, Richard Rosen, MD, DSc(Hon)
6:40-6:55 PM  **Imaging, Digital, Angiography Symposium 1**  
Moderators: John Pollack, MD; Caroline Baumal, MD  

Wide-Field Swept-Source Optical Coherence Tomography Angiography Versus Ultra-Wide Field Color Fundus Photo for Detecting Diabetic Retinopathy, **Dan Gong, MD**  

Wide-Field Swept-Source Optical Coherence Tomography Angiography Versus Fluorescein Angiography for Detecting Diabetic Retinopathy, **John Miller, MD**  

Swept-Source Optical Coherence Tomography Angiography Analysis of Intraretinal Microvascular Abnormalities, **Thomas Mendel, MD, PhD**  

The Next Generation MIOCT System: Real Time Volumetric Intraoperative Optical Coherence Tomography With 4D Visualization of Surgical Maneuvers, **Lejla Vajzovic, MD**

6:55-7:10 PM  **Imaging, Digital, Angiography Symposium 2**  
Moderators: **K. Bailey Freund, MD; Nadia Waheed, MD, MPH**  

Swept Source OCT Angiography in Vitreomacular Traction - Natural Follow-up Versus Vitreoretinal Surgery, **Zofia Michalewska, MD, PhD**  

Obstructive Sleep Apnea and Its Treatment Alter Choroidal Thickness in Patients With Central Serous Chorioretinopathy, **Carolyn Pan, MD**  

Artificial Intelligence Algorithm May Improve Performance of Retinal Specialists in Detection of Retinal Fluid on OCT in AMD: AREDS2 10-Year Study, **Michael Elman, MD**

7:10-7:35 PM  **Retinal Vascular Disease Symposium**  
Moderators: **Michael Ip, MD: James Major, Jr., MD, PhD FACS**  

Deep Learning Detection of Sea Fan Neovascularization From Ultra-Widefield Fundus Images of Sickle Cell Hemoglobinopathy, **Sophie Cai, MD**  

Real-World Treatment Patterns in Patients With Macular Edema Due to Retinal Vein Occlusion, **Vrina Hershberger, MD, PhD**  

Intravitreal Triamcinolone Acetonide in Advanced Coats’ Disease Revisited: The Results of the King Khaled Eye Specialist Hospital, **Wael Alsakran, MD**  

Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms: Results of an International Multicenter Study, **J. Fernando Arevalo, MD, PhD, FACS**  

Etiologic Profiling and Visual Outcomes of Dense Vitreous Hemorrhage Among Non-diabetics Treated With Pars Plana Vitrectomy, **Narciso Atienza, MD, MBA**
VEGF Blockage Prevents Healthy Retinal Regeneration - Noregen Promotes VEGF Modulation and Healthy In-Situ Retinal Regeneration in Vascular Disease, Michael Trese, MD

**Inflammatory & Infectious Diseases Symposium**
Moderators: Pauline Merrill, MD; Sunil Srivastava, MD

Course of Macular Edema Through 36 Months With Fluocinolone Acetonide Intravitreal Insert for Non-infectious Uveitis Affecting the Posterior Segment, Seenu Hariprasad, MD

Intraocular Pressure Following Administration of Suprachoroidal Triamcinolone Acetonide Suspension: Results From the Phase 3 PEACHTREE Clinical Trial, Quan Nguyen, MD, MSc

Outcomes of Infectious Endophthalmitis in Patients With Systemic Antibiotic Allergies or Cross Reactions to Intravitreal Vancomycin or Ceftazidime, Prethy Rao, MD, MPH

Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert, Dilraj Grewal, MD

**Surgical Techniques and Maneuvers Symposium 1**
Moderators: Young Hee Yoon, MD, PhD; Dean Eliott, MD

Sutureless Intrasceral Fixation of Intraocular Lenses: Clinical Outcomes and Comparative Effectiveness of Haptic Flanging in a Series of 488 Eyes, Ashkan Abbey, MD


A Microsurgical Vacuum Pick for Membrane Peeling Without Forceps, Carl Awh, MD

Amniotic Membrane Subretinal Transplantation to Promote Closure of Persistent Full-Thickness Macular Holes, Jessica Lee, MD

**Surgical Techniques and Maneuvers Symposium 2**
Moderators: Larry Halperin, MD; Sunir Garg, MD

Presence of Neurofilament Light Chain (Nfl) Proteins in the Vitreous Humor Can Serve as a Potential Ocular Biomarker for Neurodegeneration, Manju Subramanian, MD

Anterior Vitrectomy (AV) Versus Pars Plana Vitrectomy (PPV) in the Yamane Double Needle Technique: Refractive Outcomes and Complication Rates, Rizwan Shaikh, MD

Post Hoc Analysis of Clinical Suprachoroidal Injection Experience for Non-infectious Uveitis, Shree Kurup, MD
8:20-8:35 PM  **ReST Committee Drug Safety Update**  
Moderator: Paul Hahn, MD, PhD  
Panelists: Dean Eliott, MD; Geoffrey Emerson, MD, PhD; Jeffrey Heier, MD; Steven Yeh, MD

8:35-8:40 PM  **Poster Awards**  
Christina Weng, MD, MBA

8:40-8:45 PM  **Film Festival Awards**  
Moderators: Theodore Leng, MD; Jonathan Chang, MD

8:45-8:55 PM  **Business Meeting - Members Only**  
Timothy Murray, MD, MBA

**S A T U R D A Y ,  J U L Y  2 5**

10:00-10:25 AM  **Diabetic Retinopathy Symposium 1**  
Moderators: Jeffrey Heier, MD; Gaurav Shah, MD

Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T), Dante Pieramici, MD

Complications, Compliance, and 2-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for PDR-Related Vitreous Hemorrhage, Dennis Marcus, MD

Adjunctive Focal Laser Following Central Fluid Resolution After Bevacizumab, Ranibizumab, or Aflibercept Injection: A Secondary Analysis of Protocol T, Jennifer Gallagher, MD

Intravitreal Aflibercept Injection for Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Study, W. Lloyd Clark, MD

Incidence of New Diabetic Macular Edema in Fellow Eyes of Patients in the VISTA and VIVID Studies, Sumit Sharma, MD

Severity of Diabetic Retinopathy as an Independent Risk Factor for Cerebral Vascular Accidents, Myocardial Infarctions, and All-Cause Mortality, Bobeck Modjtahedi, MD

10:25-10:50 AM  **Diabetic Retinopathy Symposium 2**  
Moderators: John Wells, MD, FACS; W. Lloyd Clark, MD

Insights Into the Progression of Diabetic Retinopathy Severity Among Primary Care Patients With Diabetes in the United States, Geeta Lalwani, MD

Artificial Intelligence Screening for Diabetic Retinopathy: Subgroup Comparison of the EyeArt System With Ophthalmologists' Dilated Exams, Jennifer Lim, MD
Current United States Treatment Patterns for the Treatment of Proliferative Diabetic Retinopathy in the IRIS Registry, **Jeremiah Brown, MD, MS**

Switching to Combination OPT-302 With Aflibercept From Prior Anti-VEGF-A Monotherapy in Eyes With Persistent Diabetic Macula Edema (DME), **David Boyer, MD**

Diabetic Retinopathy Progression in Anti-VEGF Versus Fluocinolone Acetonide Implant Treated Eyes Who Are Lost to Follow-up, **Caesar Luo, MD**

Progression to Proliferative Diabetic Retinopathy in Nonproliferative Diabetic Retinopathy Eyes Without Diabetic Macular Edema in the United States, **Ehsan Rahimy, MD**

**10:50-11:10 AM**

**Diabetic Retinopathy Symposium 3**
Moderators: **Susan Bressler, MD; Suber Huang, MD, MBA**

Intravitreal Liposome-Encapsulated Bromfenac for the Treatment of Refractory Diabetic Macular Edema, **Hugo Quiroz-Mercado, MD**

Longitudinal Panretinal Microaneurysm and Leakage Index Evaluation in Proliferative Diabetic Retinopathy in the RECOVERY Study: 2-Year Results, **Amy Babiuch, MD**

Baseline Diabetic Retinopathy Severity Affects Time to Clinically Meaningful Improvements in Diabetic Retinopathy During Ranibizumab Treatment, **Mitchell Goff, MD**

Treatment Effect of Intravitreal Aflibercept Injection by Baseline Factors in Moderately Severe-to-Severe NPDR in PANORAMA, **Nathan Steinle, MD**

Diabetic Retinal Telescreening Program in a High-Risk Population Highlights Significant Rates of Retinal Pathology, **Matthew Ohr, MD**

**11:10-11:25 AM**

**Socioeconomic/Practice Management Symposium 1**
Moderators: **Geoffrey Emerson, MD, PhD; Tushar Ranchod, MD**

Modifier-25 Examinations Reduce Travel Burden, Decrease Treatment Cost, and Improve QALY for Exudative Age-Related Macular Degeneration Patients, **Henry Leder, MD**

Cost of Initial Aflibercept, Laser, or Observation in Eyes With Diabetic Macular Edema and Good Vision Based on Management Approaches in Protocol V, **Jennifer Sun, MD**

Physician Quality Outcome Measures Don't Reliably Measure Quality for Individual Ophthalmologists, **John Thompson, MD**
11:25-11:35 AM  **Socioeconomic/Practice Management Symposium 2**  
Moderators: Jonathan Prenner, MD; Jonathan Jonisch, MD

Medicare 2012-2017 Intravitreal Injections: Certification and Credentials of Providers, Geoffrey Emerson, MD, PhD

Opioid Prescribing Patterns and Trends of American Society of Retina Specialists (ASRS) Members, Yoshihiro Yonekawa, MD

Analysis of Emergent Non-Hospital Based Retina Consultation Requests in an Academic Non-Hospital Associated Retina Practice, Barton Blackorby, MD

11:35-11:40 AM  **Retina PractiCare 2.0 – Benchmarking Your Practice**  
John Thompson, MD

11:40-11:55 AM  **Coding and Reimbursement Update**  
Introductions: Timothy Murray, MD, MBA

Speakers: Ankoor Shah, MD; John Thompson, MD; Christina Weng, MD, MBA

11:55 AM -12:10 PM  **Hereditary Retinal Diseases & Genetics Symposium**  
Moderators: Jason Comander, MD, PhD; Eric Nudleman, MD, PhD

Intravitreal Injection of Allogeneic Human Retinal Progenitor Cells for Treatment of Retinitis Pigmentosa: Results From the Phase 2b Trial, Anthony Joseph, MD

Genetic Profile and Associated Characteristics of 265 Korean Patients With Retinitis Pigmentosa, Young Hee Yoon, MD, PhD

Correlation Between Visual Function and Macular Morphological Characteristics Evaluated by SD-OCT in X-Linked Retinoschisis, Honghua Yu, MD, PhD

AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 6-month Results From a Phase 1/2 Clinical Trial, Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS

12:10-12:25 PM  **Pediatric Retina, ROP Symposium 1**  
Moderators: Audina Berrocal, MD; Sengul Ozdek, MD, FEBO

Persistent Tunica Vasculosa Lentis as an Independent Risk Factor for Treatment in Retinopathy of Prematurity, Nimesh Patel, MD

Retinopathy of Prematurity Screening Using a Novel Method of Advanced Image Processing and Deep Machine Learning, Omar Punjabi, MD

Long-term Risk of Retinal Detachment in Pediatric Patients With Familial Exudative Vitreoretinopathy Previously Treated With Peripheral Laser, Irina De la Huerta, MD PhD
Results of Perimetry at Age of 10 Years in Severe ROP Eyes Receiving Laser or Anti-VEGF Treatment as Primary Monotherapy, Alay Banker, MD

12:25-12:40 PM  **Pediatric Retina, ROP Symposium 2**
Moderators: Mary Elizabeth Hartnett, MD; Anna Ells, MD, FRCS(C)

Efficacy of Aflibercept Treatment and Its Long-term Effect on Physiological Angiogenesis in a Mouse Model of Oxygen-Induced Retinopathy of Prematurity, Andres Gonzalez, MD

Laser Photocoagulation for Type 2 Retinopathy of Prematurity (ROP) or Less: When and Why?, Edward Wood, MD

Angiographic Review of Choroidal Involution in Eyes With Retinopathy of Prematurity Post-Bevacizumab Treatment, Swati Agarwal-Sinha, MD

Long-term Complications of Laser Treated Infants With Retinopathy of Prematurity, Audina Berrocal, MD

12:40-1:00 PM  **Surgical Techniques and Maneuvers Symposium 3**
Moderators: Fabio Patelli, MD; Dante Pieramici, MD

Creating Blebs for Subretinal Gene Delivery, Andreas Lauer, MD

Refractive Outcomes After Sutureless Intrasceral Fixation of Secondary Intraocular Lens With Pars Plana Vitrectomy, Ramon Lee, MD

Macular Support for Posterior Staphyloma in High Myopia - Does Buckle Have a Beneficial Effect in Myopic Tractional Maculopathy?, Pradeep Susvar, DNB, FRCS(Glasg), MBA

Update on Paracentral Retinotomy for Resistant Macular Hole, Michael Tsipursky, MD

Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated With Vitreoretinal Surgery, Daniel Kiernan, MD, FACS

1:00-1:15 PM  **Surgical Techniques and Maneuvers Symposium 4**
Moderators: Marco Mura, MD; Elliott Sohn, MD

Intraoperative OCT Guided Vitrectomy for Optic Pit Maculopathy, Makoto Inoue, MD

Comparative Assessment of Conventional Microscope-Integrated to Digitally-Enabled Intraoperative OCT in Vitreoretinal Surgery in the DISCOVER Study, Katherine Talcott, MD

Comparative Study of Single Port Versus Dual Port Vitrectomy for the Treatment of Vitreous Opacities, Luiz Lima, MD
Visual Acuity Outcome in Patients With Subretinal Hemorrhage, Office Procedure Versus Surgical Treatment, Rita Ehrlich, MD

1:15-1:25 PM  **Surgical Techniques and Maneuvers Symposium 5**  
Moderators: Carl Regillo, MD; Ehab El-Rayes, MD, PhD

Acute Intraoperative Hypotony During Automated Infusion Control, Raymond Iezzi, MD, MS

Real-World Visual Outcomes After YAG Vitreolysis for Vitreous Opacities (VOYAGE), Netan Choudhry, MD, FRCS(C)

Evaluation of the Intra-operative Efficiency of a Novel Hypersonic Vitrector in Typical Clinical Settings, Victor Gonzalez, MD

1:25-1:35 PM  **Ocular Oncology Symposium**  
Moderators: Prithvi Mruthunjaya, MD, MHS; Tara McCannel, MD, PhD

Complex Ocular Oncology: Evolving Treatments in the Absence of Clinical Trials - 3 Decades Focused on Decreasing Treatment Related Morbidity/Mortality, Timothy Murray, MD, MBA

Update From an Ongoing Phase 1b/2 Open-label Clinical Trial Evaluating the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma, Ivana Kim, MD

1:35-1:55 PM  **Retinal Detachment Symposium**  
Moderators: Tarek Hassan, MD; Kourous Rezaei, MD;

Management of Proliferative Vitreoretinopathy With Intravitreal Methotrexate Using a Treat-and-Extend Protocol, Scott Walter, MD, MSc

Clinicopathologic Correlations of Retinal Membranes Associated With Intravitreal “Stem Cell” Injections, Rehan Hussain, MD

Outcomes of Sub-silicone Oil Triamcinolone Acetonide Application After 3600 Relaxing Retinectomy for Complex Retinal Detachments – A Comparative Study, Subhendu Boral, MBBS, MD(AllMS), DNB(OPHTHALMOLOGY)

Single Cell Genome-Wide Expression Profiling of Patient-Derived Membranes in Proliferative Vitreoretinopathy, Leo Kim, MD, PhD

Effect of Etiology on the Outcome in Pediatric Rhegmatogenous Retinal Detachment Undergoing Small Gauge Vitrectomy With Silicon Oil, Navneet Mehrotra, DNB
1:55-2:10 PM  
**Macular Surgery Symposium 1**  
Moderators: **Ivana Kim, MD; Mrinali Gupta, MD**

Multilayered Inverted Internal Limiting Membrane Flap - A Unique Technique for Closure of Large Macular Holes, **Srinivas Joshi, MD**

Spontaneous Conversion of Lamellar Macular Holes to Full-Thickness Macular Holes: Clinical Features and Surgical Outcomes, **Ismael Chehaibou, MD**

Clinical Characteristics, Risk Factors, and Surgical Outcomes of Secondary Macular Hole After Vitrectomy, **Min Kim, MD**

2:10-2:25 PM  
**Macular Surgery Symposium 2**  
Moderators: **Francesco Boscia, MD; Barbara Parolini, MD**

Comparison of the Embedding and Sparing Technique in Treating Lamellar Macular Holes With Lamellar Hole-Associated Epiretinal Proliferation, **Tso-Ting Lai, MD**

Relation of Anatomy With Function Following the Surgical Treatment of Idiopathic Epiretinal Membrane: A Multicentric Retrospective Study, **Sengul Ozdek, MD, FEBO**

Limited Vitrectomy for Epiretinal Membranes: A Comparative Multi-Center Trial, **Matteo Forlini, MD**

2:25-2:30 PM  
**Closing Message**  
Timothy Murray, MD, MBA and Philip Ferrone, MD

**SUNDAY, JULY 26**

10:00-10:15 AM  
**Dry-AMD Symposium 1**  
Moderators: **David Sarraf, MD; Sophie Bakri, MD**

Pentosan Polysulfate Maculopathy Versus Age-Related Macular Degeneration: Comparative Assessment With Multimodal Imaging, **Joseph Christiansen, MD**

Pentosan Polysulfate Maculopathy: Disease Course After Drug Cessation, **Rachel Shah, MD**

Phase 1 Safety Study of Intravitreal (ITV) Anti-High Temperature Requirement A1 (aHtrA1), a Novel Serine Protease Inhibitor, in Patients With GA, **William Bridges, MD**

Impact of Baseline OCT Characteristics on Response to Risuteganib for the Treatment of Intermediate Age-Related Macular Degeneration, **Justis Ehlers, MD**
10:15-10:30 AM  **Dry-AMD Symposium 2**  
Moderators: Fernando Arevalo, MD, PhD, FACS; Arshad Khanani, MD

Role of Metabolomics in Age-Related Macular Degeneration, Deeba Husain, MD

Nonneovascular Age-Related Macular Degeneration and Fluid, David Sarraf, MD

Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD, Baruch Kuppermann, MD, PhD

Cognitive Testing in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Wet Age-Related Macular Degeneration, Subhransu K. Ray, MD, PhD

10:30-10:50 AM  **Wet-AMD Symposium 1**  
Moderators: Philip Ferrone, MD; David Brown, MD

Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD, Peter Campochiaro, MD

Intravitreal Gene Therapy for Neovascular AMD With ADVM-022: Results of the Phase 1 OPTIC Trial, Charles Wykoff, MD, PhD

Characteristics of Fellow Eye Conversion to Neovascular Age-Related Macular Degeneration in Patients With Unilateral Neovascular Disease, Matthew Starr, MD

High-dose Aflibercept Therapy in nAMD and DME Eyes With Suboptimal Response to Standard Dose of Anti-VEGF Therapy: A Retrospective Analysis, Jared Nielsen, MD, MBA

Anti-VEGF Resistant Subretinal Fluid Associated With Reduced Risk of Macular Atrophy and Better Vision: Drug-Induced Choroidal New Vessel Homeostasis?, Marco Zarbin, MD, PhD

10:50-11:10 AM  **Wet-AMD Symposium 2**  
Moderators: Allen Ho, MD; Nathan Steinle, MD

RGX-314 for Neovascular AMD: Ongoing Phase I/IIa Results for Cohorts 1-5, Arshad Khanani, MD

Comparative Efficacy of Different Anti-VEGF Treatment Regimens in Patients With nAMD: A Network Meta-Analysis, Diana Do, MD

Agitation of the Syringe as a Cause of Inflammation After Intravitreal Injection of Aflibercept: A Randomized, Double-blind, Controlled Clinical Trial, Gustavo Melo, MD, PhD
Performance of a Novel Deep Learning Algorithm for Automatic Retinal Fluid Quantification in Home OCT Images, Judy Kim, MD

Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER, Carl Regillo, MD

11:10-11:25 AM  
**Wet-AMD Symposium 3**  
Moderators: Christina Weng, MD, MBA; Lisa Olmos de Koo, MD, MBA

One-Year and Beyond: Results of Phase 1b Study of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO, Mark Barakat, MD

Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results, Peter Kertes, MD, FRCS(C)

Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections, Nancy Holekamp, MD

Two-Year Real-World Treat and Extend Patterns and Fluid Outcomes Among Neovascular Age-Related Macular Degeneration Patients Treated With Anti-VEGFs, Michael Singer, MD

11:25-11:35 AM  
**Wet-AMD Symposium 4**  
Moderators: Mark Humayun, MD, PhD; Diana Do, MD

Loss to Follow-up in Patients With Neovascular Age-Related Macular Degeneration Treated With Anti-VEGF Therapy in the United States, Rahul Khurana, MD

Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD, Rahul Komati, MD

Suprachoroidal CLS-AX (axitinib injectable suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD), David Brown, MD

11:35-11:55 AM  
**Wet-AMD Symposium 5**  
Moderators: Baruch Kuppermann, MD, PhD; Leo Kim, MD, PhD

Association Between CRT Fluctuation and BCVA With Abicipar Pegol Administered Every 12 Weeks for Neovascular AMD: CEDAR and SEQUOIA 52-Week Data, Jeremy Wolfe, MD, MS

Intravitreal AAVCAGsCD59 as Adjunct Anti-VEGF Treatment for Wet Age-Related Macular Degeneration (AMD), Jeffrey Heier, MD

Sustained Biweekly Aflibercept Improves Vision and Reduces Persistent Fluid in Refractory Neovascular AMD: Results From the Prospective TRISTAR Study, Eric Schneider, MD
Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) End of Study Results, David Eichenbaum, MD

Fluctuations in Central Foveal Thickness and Vision Outcomes With Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration, Veeral Sheth, MD, MBA

Wet-AMD Symposium 6
Moderators: Peter Kaiser, MD; David Eichenbaum, MD
Clinical Effects of Blocking Ang-2 and VEGF With Faricimab in the Phase 2 STAIRWAY Trial, Carl Danzig, MD
Peripheral Exudative Haemorrhagic Chorioretinopathy - A New Addition to the Spectrum of Pachychoroid Disease?, Daraius Shroff, MS FMRF FRCS
Abicipar Phase 2 MAPLE Trial: Evaluation of All Patients With Post-Injection Inflammation, Tarek Hassan, MD
Effects of Ketoconazole on Clinical Recovery, Choroidal Thickness and Hormonal Profile in Patients With Central Serous Chorioretinopathy, Yodpong Chantarasorn, MD
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab: From PRN Refills in Phase 2 Ladder to Fixed 24-Week Refills In Phase 3 Archway, Dilsher Dhoot, MD

Wet-AMD Symposium 7
Moderator: Jay Duker, MD; Judy Kim, MD
Predicting Long-term Response to Ranibizumab After Three Injections in Patients With Age-Related Macular Degeneration, Paul Hahn, MD, PhD
Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Choroidal Neovascularization in AMD (ForeseeHome Device), Allen Ho, MD
Combination of Dexamethasone Implant and Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration, Raja Narayanan, MD, MBA
Ten-Year Follow-up of Patients With Exudative Age-Related Macular Degeneration Treated With Intravitreal Anti-VEGF Injections, Sophie Bakri, MD
Clinical Evaluation and PK/PD Modeling of the DARPin Therapeutic Abicipar for the Treatment of Neovascular Age-Related Macular Degeneration, Peter Kaiser, MD

Instrumentation & Devices Symposium 1
Moderators: Carl Awh, MD; David Chow, MD, FRCS(C)

The Effect of Latency on Digital Vitreoretinal Surgery, David Tri Ta Kim, MD FRCSC

Cooling Anesthesia for Intravitreal Injection With a Novel Device: Results of the Prospective COOL-2 Study, Daniel Chao, MD, PhD

Microscope-Integrated Optical Coherence Tomography Can Measure the Volume of Subretinal Blebs Created by a Suprachoroidal Approach, Ananth Sastry, MD

Results From the Phase 3 PEACHTREE Clinical Trial: Systemic Therapy and the Efficacy of CLS-TA, a Post Hoc Analysis, Ashvini Reddy, MD

12:50-1:00 PM Instrumentation & Devices Symposium 2
Moderators: J. Michael Jumper, MD; Jorge Fortun, MD

Lens and Peripheral Retinal Relationships During Vitrectomy: Comparison of 23, 25, and 27-Gauge Vitrectomy and Curved Endolaser Probes, Jayanth Sridhar, MD

Particulate Matter From Syringes Used for Intravitreal Injections, Roger Goldberg, MD, MBA

Post Hoc Analysis of Suprachoroidal Injection Experience Across Retinal Disease Indications, Christopher Henry, MD

1:00-1:15 PM Pediatric Take-Home Panel
Moderator: Darius Moshfeghi, MD

Panelists: Kimberly A. Drenser, MD; Jessica G. Lee, MD; Lejla Vajzovic, MD; Yoshihiro Yonekawa, MD

1:15-1:30 PM Diabetic Retinopathy Take-Home Panel
Moderator: Charles Wykoff, MD, PhD

Panelists: Robert L. Avery, MD; Maria H. Berrocal, MD; Nancy M. Holekamp, MD; J. Michael Jumper, MD

1:30-1:45 PM AMD Take-Home Panel
Moderator: David Boyer, MD

Panelists: Neil M. Bressler, MD; Margaret A. Chang, MD; Jennifer I. Lim, MD; Aleksandra V. Rachitskaya, MD

1:45-1:50 PM Closing Message
Timothy Murray, MD, MBA; Philip Ferrone, MD

Accreditation Statement and CME Credit
The American Society of Retina Specialists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Retina Specialists designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.